Login to Your Account



Financings NEWS

LAM Therapeutics, a portfolio company of Connecticut biotech start-up incubator 4Catalyzer, closed a $40 million financing to advance lead programs, LAM-001, an inhaled mTOR kinase Inhibitor in phase I development to treat lymphangioleiomyomatosis – also known as LAM lung disease – and LAM-002, a selective kinase inhibitor that is cytotoxic for certain cancers with little or no effect on normal cells.

SHANGHAI – Suzhou, China-based Adagene Inc. received $28 million in series B financing to further enhance its technology-driven antibody discovery platform and nudge its own portfolio of innovative antibodies, against targets related to cancer and other diseases, closer to the clinic.

Blend Therapeutics Inc. said it will use a $38 million series C equity financing to carry a new lead candidate for neuroendocrine cancers into phase I studies by mid-year and what president and CEO Drew Fromkin told BioWorld Today will be "well through major data inflection points."

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: